Company Description
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo.
The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
| Country | United States |
| Founded | 1997 |
| IPO Date | Oct 29, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 83 |
| CEO | Dr. Hermann Luebbert Ph.D. |
Contact Details
Address: 120 Presidential Way, Suite 330 Woburn, Massachusetts 01801 United States | |
| Phone | 781-245-1325 |
| Website | biofrontera.us.com |
Stock Details
| Ticker Symbol | BFRI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001858685 |
| CUSIP Number | 09077D100 |
| ISIN Number | US09077D2099 |
| Employer ID | 47-3765675 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hermann Luebbert Ph.D. | Chief Executive Officer, President and Executive Chairman |
| Eugene Frederick Leffler III | Chief Financial Officer |
| Erica F. Gates CPA, M.B.A. | Senior Director of Finance and Principal Accounting Officer |
| Jon Lyons M.B.A., Ph.D. | Vice President of Scientific and Medical Affairs |
| Alycia Torres | Vice President of Administration |
| Daniel Hakansson J.D. | General Counsel and Head of Compliance |
| Samantha Widdicombe | Senior Director of Strategic Accounts and Communications |
| Mark Baldyga | Vice President of Sales and Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | 8-K | Current Report |
| Apr 22, 2024 | EFFECT | Notice of Effectiveness |
| Apr 17, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2024 | 8-K/A | [Amend] Current report |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 21, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 20, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 20, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 20, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |